icd 10 code for synagis shot

by Izabella Renner 9 min read

Encounter for prophylactic immunotherapy for respiratory syncytial virus (RSV) Z29. 11 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM Z29.

How do you code Synagis injection?

Billing Information - Billing on the medical benefit requires submission of a claim form using CPT code 90378 for Synagis®, with required NDC and billing units incremental to each 50 mg dose administered (i.e. 100 mg = 2 billing units).

What is CPT code for Synagis?

Billing and payment for pre-approved Synagis® administration, outside of the specialty pharmacy provider, requires submission of a claim form using the designated CPT 90378 for Synagis®, with a required NDC and entry of billing units incremental to each 50 mg dose administered (i.e. 100mg = 2 billing units).

Is Synagis a vaccine or immunization?

SYNAGIS [si-nah-jis] helps protect babies from RSV through virus-fighting antibodies. SYNAGIS is not a vaccine—it's an injection given once a month throughout RSV season, which usually starts in the fall and continues into spring.

Does Synagis have AJ code?

Synagis J Code We use both 90378 and J3490, based on our contract with the individual payors.

How do I code RSV?

ICD-10 Code for Respiratory syncytial virus as the cause of diseases classified elsewhere- B97. 4- Codify by AAPC.

What is procedure code 90378?

The Current Procedural Terminology (CPT®) code 90378 as maintained by American Medical Association, is a medical procedural code under the range - Immune Globulins, Serum or Recombinant Products.

Is there an immunization for RSV?

Currently, there is no cure or vaccine for RSV – the medical world is limited to offering only supportive care, such as oxygen and fluids, for those with the illness.

What is RSV prophylaxis?

Through the Respiratory Syncytial Virus Prophylaxis for High-Risk Infants Program, the Ministry of Health covers the full cost of the drug palivizumab used to prevent a serious lower respiratory tract infection caused by the Respiratory Syncytial Virus ( RSV ) in infants who are less than 2 years of age at the start of ...

What is in the RSV shot?

Synagis® (palivizumab) for infants is an FDA-approved prescription, made up of virus-fighting antibodies, which helps prevent serious respiratory tract infections caused by respiratory syncytial virus (RSV). While Synagis® is not a vaccine, it can help high-risk infants by protecting them from severe RSV disease.

What is the criteria for Synagis?

Chronic Lung Disease (CLD) of prematurity (defined as birth at less than 32 weeks 0 days gestation and requiring greater than 21 percent oxygen for at least 28 days after birth).

What CPT code replaced 90772?

96372The Current Procedural Terminology (CPT) code 90772 has been deleted from available CPT codes and replaced with CPT code 96372. The description stays the same: “therapeutic, prophylactic, or diagnostic injection (specify material injected); subcutaneous or intramuscular.”

What is the CPT code for palivizumab?

Effective for dates of service on or after 10/19/2018 standard National Correct Coding Initiative (NCCI) Procedure to Procedure (PTP) editing will be applied to the administration code (CPT 96372) and Evaluation and Management (E/M) Service combination when rendered on the same date of service by the same provider.

Policy

Dosage and Administration

  • The dosage and administration information are based on the FDA-approved Prescribing Information. See Appendix A for recommendations from the American Academy of Pediatrics (AAP). Palivizumab is available as Synagis for injection as 50 mg per 0.5 mL and 100 mg per 1 mL single-dose liquid solution vials for intramuscular use. The recommended dose of Synagis is 15 …
See more on aetna.com

Experimental and Investigational

  • Aetna considers palivizumab experimental and investigational for all other indications (not an all-inclusive list): 1. Asthma 2. Down syndrome 3. Childhood interstitial lung disease (chILD) 4. Prevention of health-care associated RSV disease 5. Prophylaxis against RSV in immunocompromised adults 6. Treatment of RSV.
See more on aetna.com

Background

  • U.S. Food and Drug Administration (FDA)-Approved Indications
    Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients: 1. with a history of premature birth (less than or equal to 35 weeks gestational age) and who are 6 months of age or younger at the begin…
  • Compendial Uses
    1. RSV prophylaxis in infants with congenital abnormalities of the airway or neuromuscular disease that compromise handling of respiratory secretions 2. RSV prophylaxis in immunocompromised pediatric patients 3. RSV prophylaxis in pediatric patients with cystic fibro…
See more on aetna.com

Appendix

  • Appendix A: Recommended Use of Synagis for Prevention of RSV Infection
    Recommendations from the American Academy of Pediatrics (AAP) for the prevention of RSV infection with Synagis are summarized in Table below. Synagis should be administered intramuscularly at a dose of 15 mg/kg once per month beginning prior to the onset of the RSV s…
  • Appendix B: Examples of Congenital Heart AnomaliesFootnote2**
    1. Atrial or ventricular septal defect 2. Patent ductus arteriosus 3. Coarctation of aorta 4. Tetralogy of Fallot 5. Pulmonary or aortic valve stenosis 6. D-Transposition of great arteries 7. Hypoplastic left/right ventricle 8. Truncus arteriosus 9. Total anomalous pulmonary venous retur…
See more on aetna.com